Kazia Share Purchase Plan Raises AU$0.8M, Taking Total Funds Raised to AU$4.2M

KEY TAKEAWAYS:

• Kazia announce the Share Purchase Plan (SPP), has now been successfully completed.
• SPP achieved subscriptions from eligible shareholders amounting to approximately A$0.8 million
• Total proceeds of this financing round equated to AU$4.2 million (before costs)
• Kazia Chairman, Iain Ross, commented, “we have been delighted to receive applications to participate in the SPP from 130 shareholders

Sydney, 20 November 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the Share Purchase Plan (SPP), as described in the SPP booklet dated 23 October 2018, has now been successfully completed.

The SPP achieved subscriptions from eligible shareholders amounting to approximately A$0.8 million, bringing the total proceeds of this financing round to AU$4.2 million (before costs). The final figure is subject to clearance of cheques. All of the directors of Kazia participated to the full extent of their entitlement. The new shares will be issued on 23 November 2018 and will be freely tradeable on the ASX from 26 November 2018.

The SPP offered eligible shareholders the opportunity to apply for up to A$15,000 worth of new fully paid ordinary shares in Kazia, without incurring brokerage or other transaction costs. Shares under the SPP were offered at a price of A$0.38 per share, which was equal to the price under the institutional placement announced by Kazia on 18 October 2018, in which AU$ 3.4M was raised primarily from sector-specialist institutional investors.

Kazia Chairman, Iain Ross, commented, “we have been delighted to receive applications to participate in the SPP from 130 shareholders, ranging from members of the top twenty investors to holders of just a few hundred shares.

The proceeds of the SPP, when added to the recent institutional placement, will strengthen the company’s balance sheet considerably, and leave us confident of being able to complete the ongoing phase IIa GDC-0084 study and the ongoing phase I Cantrixil study. In addition, the new monies from the SPP will allow us to contemplate additional collaborations and partnerships such as those recently announced with St Jude Children’s Research Hospital and Dana-Farber Cancer Institute.”

He added, “this is a challenging market for biotech at present, and the SPP has significantly exceeded expectations. We are grateful as always for the very substantial support of our shareholders. The funds raised through the SPP put the company in a strong position to deliver significant, value-driving clinical data read-outs throughout calendar 2019.”

About Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA)

Kazia Therapeutics is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical stage drug development candidates, and we are working to develop therapies across a range of
oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC0084 entered a phase II clinical trial in March 2018. Initial data is expected in early calendar 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented in June 2018 and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

Register Interest